259 related articles for article (PubMed ID: 19363908)
1. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne.
Webster G; Cargill DI; Quiring J; Vogelson CT; Slade HB
Cutis; 2009 Mar; 83(3):146-54. PubMed ID: 19363908
[TBL] [Abstract][Full Text] [Related]
2. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
[TBL] [Abstract][Full Text] [Related]
3. Tretinoin microsphere gel in younger acne patients.
Jorizzo J; Grossman R; Nighland M
J Drugs Dermatol; 2008 Aug; 7(8 Suppl):s9-13. PubMed ID: 18724649
[TBL] [Abstract][Full Text] [Related]
4. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis.
Nighland M; Grossman R
J Drugs Dermatol; 2008 Aug; 7(8 Suppl):s2-8. PubMed ID: 18724648
[TBL] [Abstract][Full Text] [Related]
5. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
[TBL] [Abstract][Full Text] [Related]
6. Comparison of micronized tretinoin gel 0.05% and tretinoin gel microsphere 0.1% in young adolescents with acne: a post hoc analysis of efficacy and tolerability data.
Lucky AW; Sugarman J
Cutis; 2011 Jun; 87(6):305-10. PubMed ID: 21838089
[TBL] [Abstract][Full Text] [Related]
7. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris.
Thiboutot D; Gold MH; Jarratt MT; Kang S; Kaplan DL; Millikan L; Wolfe J; Loesche C; Baker M
Cutis; 2001 Oct; 68(4 Suppl):10-9. PubMed ID: 11845943
[TBL] [Abstract][Full Text] [Related]
9. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults.
Berger R; Barba A; Fleischer A; Leyden JJ; Lucky A; Pariser D; Rafal E; Thiboutot D; Wilson D; Grossman R; Nighland M
Cutis; 2007 Aug; 80(2):152-7. PubMed ID: 17944177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study.
Jarratt MT; Brundage T
J Drugs Dermatol; 2012 Mar; 11(3):318-26. PubMed ID: 22395582
[TBL] [Abstract][Full Text] [Related]
11. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment.
Leyden JJ; Shalita A; Thiboutot D; Washenik K; Webster G
Clin Ther; 2005 Feb; 27(2):216-24. PubMed ID: 15811485
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
Eichenfield LF; Alió Sáenz AB
J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
[TBL] [Abstract][Full Text] [Related]
13. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris.
Cunliffe WJ; Danby FW; Dunlap F; Gold MH; Gratton D; Greenspan A
Eur J Dermatol; 2002; 12(4):350-4. PubMed ID: 12095880
[TBL] [Abstract][Full Text] [Related]
14. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne.
Richter JR; Förström LR; Kiistala UO; Jung EG
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):227-33. PubMed ID: 9883434
[TBL] [Abstract][Full Text] [Related]
16. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris.
Shalita AR; Rafal ES; Anderson DN; Yavel R; Landow S; Lee WL
Cutis; 2003 Aug; 72(2):167-72. PubMed ID: 12953944
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
18. Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study.
Eichenfield LF; Hebert AA; Schachner L; Paller AS; Rossi AB; Lucky AW
Pediatr Dermatol; 2012; 29(5):598-604. PubMed ID: 22712470
[TBL] [Abstract][Full Text] [Related]
19. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
Webster GF; Berson D; Stein LF; Fivenson DP; Tanghetti EA; Ling M
Cutis; 2001 Jun; 67(6 Suppl):4-9. PubMed ID: 11499329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
